Video

Safety And Efficacy Advancements In Genome Editing

Source: Cell & Gene

Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics shares his take on the high frequency of productive edits for base editing. In addition, given Celularity’s focus on placental-derived cells, here, the company’s Chairman, Founder, and CEO, Dr. Robert Hariri, shares how he sees non-viral gene delivery methods potentially enhancing cell therapy platforms and how non-viral methods are poised to revolutionize the landscape of gene therapy in general.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)